HLA studies in IgM rheumatoid-factor-positive arthritis of childhood

L. E. Clemens, E. Albert and B. M. Ansell

From the 1Juvenile Rheumatism Unit, Taplow, the 2Clinical Research Centre, Harrow, and the 3National Reference Tissue Typing Laboratory, Munich

SUMMARY  The clinical course of children with IgM rheumatoid-factor-positive chronic arthritis closely resembles that of seropositive rheumatoid disease in adults. The frequency of HLA DR4 is known to be increased in adults with seropositive rheumatoid arthritis, but the first major report on childhood arthritis did not suggest a correlation, though only 8 seropositive cases were included. Fifty-two children with polyarthritis beginning before the age of 16 who persistently carried IgM rheumatoid factor were studied. HLA DR4 was present in 60% of these children but was found in only 29% of 93 patients with seronegative juvenile arthritis and 27% of a normal adult population. These results suggest immunogenetic similarities in patients with seropositive arthritis irrespective of age of onset.

Only a small proportion of patients with childhood onset arthritis persistently carry IgM rheumatoid factor (RF). A recent computer analysis of 148 patients with juvenile chronic arthritis (JCA) seen within 3 months of onset showed that 6% carried IgM, RF, and their disease was characterised by a polyarticular onset progressing rapidly to bony erosions. Seropositivity is known to be more common with increasing age of onset, and there is a marked female preponderance in patients affected. The association of HLA DR4 with adult rheumatoid arthritis is well established. However, Stastny and Fink reported different HLA D associations in adults and children and noted HLA DR4 in only 1 of 8 children with seropositive arthritis compared with 70% in adults. This apparent difference between adult- and childhood-onset RF-positive arthritis prompted us to study HLA antigen distribution in a larger group of such patients.

Materials and methods

Patients. Fifty-two children, 43 girls and 9 boys, whose arthritis began before the age of 16 were studied. All fulfilled the criteria for diagnosis of juvenile chronic arthritis and persistently carried IgM rheumatoid factor, as shown by repeatedly positive results, over the first year of illness, for both the latex test using human IgG substrate and sensitised sheep red cell tests using rabbit IgG.

Clinical data. Clinical, radiological, and laboratory measures of disease activity and severity were assessed at the onset of disease and at 2 and 5 years. An attempt was made to correlate findings with HLA types and to identify clinical subgroups.

Controls. HLA antigen frequencies for English Caucasians from Histocompatibility Testing 1980 were used to provide normal control figures, with the population size being reduced to equal that of the patient group. As part of a programme of genetic studies in juvenile chronic arthritis we have typed 93 children with seronegative JCA, and these patients provided a seronegative control group.

HLA typing. HLA A, B, C, and DR typing was carried out on peripheral blood lymphocytes by a standard complement-dependent cytotoxicity method. Twelve A-locus, 16 B-locus, 7 C-locus, and 10 DR-locus antigens were tested.

Statistical analysis. Differences in antigen frequencies between the patient and control groups were tested for significance by Fisher's exact test, corrected for the number of antigens tested. The same method was used to evaluate associations between clinical features and HLA antigens.

Results

Altered antigen frequencies. Several antigens showed altered frequencies (Table 1). The only one to show significance was HLA DR4, which was present in
patients with seropositive childhood arthritis compared with normal controls and seronegative juvenile chronic arthritis

<table>
<thead>
<tr>
<th>Antigens</th>
<th>Seropositive childhood arthritis (n = 52) %</th>
<th>Seronegative JCA (n = 93) %</th>
<th>Normal controls %</th>
<th>p value (corrected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR1</td>
<td>25</td>
<td>13</td>
<td>13</td>
<td>NS</td>
</tr>
<tr>
<td>DR2</td>
<td>10</td>
<td>25</td>
<td>19</td>
<td>NS</td>
</tr>
<tr>
<td>DR4</td>
<td>60</td>
<td>29</td>
<td>27</td>
<td>0.007</td>
</tr>
<tr>
<td>DR5</td>
<td>21</td>
<td>28</td>
<td>19</td>
<td>NS</td>
</tr>
<tr>
<td>B8</td>
<td>44</td>
<td>26</td>
<td>29</td>
<td>NS</td>
</tr>
<tr>
<td>B27</td>
<td>15</td>
<td>10</td>
<td>8</td>
<td>NS</td>
</tr>
</tbody>
</table>

60% (p (corrected) = 0.007) of seropositive subjects, which contrasted with the first 93 typed seronegative patients, of whom 29% carried HLA DR4. The control group of normal adults showed a frequency of 27% for this antigen. There was an increase in HLA B8, B27, and DR1 and a decrease in HLA DR2 in the group under study, but none of these was statistically significant.

**Family studies.** The parents and siblings of 16 patients were also studied to define HLA haplotypes and homozygosity. In 5 families there was a history of adult rheumatoid arthritis, a grandparent in 4, and uncle in one; one of these cases was seen and confirmed as seropositive rheumatoid arthritis. There were no cases of affected sibling pairs. Ten of the 16 probands were DR4-positive, 2 being homozygous, but DR4 did not appear to be associated with any particular haplotype. Five carried the B8, DR3 haplotype. In 4 families there were siblings who did not have disease but shared both haplotypes with the proband.

**Clinical parameters.** The mean age of onset was 10-9 years (3 to 15); 25% of patients had a family history of rheumatoid arthritis. A review of x-rays showed that all had developed widespread erosions within 5 years of onset of their disease, with most having these changes present at 2 years. Long-acting drugs had been given to 85% of patients within the first 5 years of disease; toxic reactions to them had occurred in 23% of cases. Arthroplasty, usually of the hip, had been performed in 39% of our patients. A comparison of findings in patients who were DR4-positive with those who were negative revealed 2 trends (Table 2); in particular, rheumatoid nodules were more frequent in DR4-positive patients, and toxicity to long-acting drugs was more common in DR4-negative patients. There was no difference with respect to mean age at onset, family history of rheumatoid arthritis, and frequency of arthroplasty.

**Toxicity to long-acting antirheumatic drugs.** Toxic reactions requiring treatment to be stopped occurred during 8 of 29 courses of gold in 27 children and 6 of 18 courses of penicillamine in 18 children (Table 3). Proteinuria greater than 2 g daily developed in 3 patients (2 on gold, one on penicillamine); none carried DR3. Seven patients developed a rash (6 on gold, one on penicillamine); 4 of these patients did carry DR3. Two patients developed side effects to both penicillamine and gold; the toxic reactions were dissimilar in both cases; one patient was DR3-positive. These numbers are too small to allow statistical evaluation.

**Discussion**

Clinically the heterogeneity of childhood arthritis is well recognised, and HLA studies have revealed significant alterations in antigen frequencies in several subgroups. The strongest association is that of HLA B27 with juvenile ankylosing spondylitis and postdysenteric arthritis. Examination of clinically defined subgroups of JCA has revealed other associations. Glass et al. found an increased frequency of HLA DR5 in patients with early-onset pauciarticular disease, chronic iridocyclitis, and positive antinuclear antibodies. Stastny and Fink found the HLA D anti- gen TMo in 46% of their patients with persistent pauciarticular arthritis, while Morling et al. described increased HLA DW5 and DW8 and decreased DW/DR-2 in their patients in this subgroup. Høversaa et al. in a study of 77 patients found increased DR5 and DR8 in those with a pauciarticular onset but did not divide their group into persisting pauciarticular and progression to polyarthritis. An increase in antigens HLA B27 and B17 has been

---

**Table 1** HLA antigens showing altered frequency in 52 patients with seropositive childhood arthritis compared with normal controls and seronegative juvenile chronic arthritis

**Table 2** Clinical findings in HLA DR4-positive and HLA DR4-negative patients with seropositive childhood arthritis

**Table 3** Toxic reactions to gold and penicillamine in seropositive childhood arthritis
described in juvenile psoriatic arthritis, and it has been suggested that presence of B17 is associated with mild arthritis.16

Our results in patients with seropositive childhood arthritis differ from those of Stastny and Fink, who found HLA DR4 in only one of their 8 latex-positive polyarticular patients.3 This low frequency of HLA DR4, compared with 60% in our group, may be entirely due to the small number of patients included, but the factors of race and patient selection must also be considered. All our patients were Caucasian and had persistently positive tests for rheumatoid factor by both latex and sensitised sheep red cell tests; most had been followed up for at least 5 years. We purposely excluded patients with an intermittently weakly positive latex or red cell agglutination test or a single positive result. Our findings and those of Høyeraa et al.,11 who showed an increased frequency of HLA DR4 in a small group of children with Rose-Waaler-positive polyarthritides, suggest immunogenetic similarities in adults and children with seropositive disease.

The potential severity of seropositive polyarthritis in childhood has been recognised for some time,17 but only recently has the radiological progression and response to long-acting drug therapy been reported.18 19 The high incidence of destructive joint disease, arthroplasty, and the need for long-acting antirheumatic drugs in our group highlights the aggressiveness of the disease and contrasts with the natural history of seronegative polyarticular JCA.17

We sought HLA associations in our patients which might be useful in predicting disease prognosis or response to therapy. The recognised association between HLA DR3 and the development of proteinuria in adults with rheumatoid arthritis treated with gold or penicillamine20 prompted us to examine antigen frequencies in our patients with toxic reactions to these long-acting drugs. Although toxic reactions occurred during one-quarter of the gold courses and one-third of the penicillamine courses, there were insufficient cases of proteinuria or rash to allow significant antigen associations to be demonstrated.

No single antigen was associated with a specific prognosis; in particular the presence of HLA DR4 did not correlate with disease severity as determined by the need for arthroplasty. Homozygosity for DR4 has been reported to be associated with 'extraordinarily severe disease' in adult rheumatoid arthritis.31 Two patients in our group, found to be DR4 homozygotes by family typing, suffered particularly severe disease, requiring multiple arthroplasties within 5 years and, in one, replacement of the aortic valve. However, disease of similar severity was present in DR4 heterozygotes and DR4-negative patients.

A further finding of interest from the families studied was the identification of 4 healthy siblings who shared both unaffected with affected probands. This is in agreement with studies of rheumatoid arthritis and other HLA-linked diseases and suggests that environmental factors and gene loci distant from the major histocompatibility complex may contribute to disease susceptibility.

This study confirms that arthritis in childhood associated with IgM rheumatoid factor is frequently severe, destructive, and progressive and establishes that there are immunogenetic similarities in patients with seropositive arthritis irrespective of age of onset.

This work was supported in part by the Stiftung Volkswagenwerk and the Medical Research Council.

References

Clemens, Albert, Ansell


HLA studies in IgM rheumatoid-factor-positive arthritis of childhood.
L E Clemens, E Albert and B M Ansell

doi: 10.1136/ard.42.4.431

Updated information and services can be found at:
http://ard.bmj.com/content/42/4/431

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/